NASDAQ:ALKS Alkermes (ALKS) Stock Price, News & Analysis $28.33 +0.24 (+0.85%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Alkermes Stock (NASDAQ:ALKS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alkermes alerts:Sign Up Key Stats Today's Range$28.03▼$28.4550-Day Range$25.94▼$29.0552-Week Range$22.01▼$32.88Volume1.48 million shsAverage Volume1.83 million shsMarket Capitalization$4.79 billionP/E Ratio16.86Dividend YieldN/APrice Target$36.70Consensus RatingModerate Buy Company OverviewAlkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Read More… Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Alkermes Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks95th Percentile Overall ScoreALKS MarketRank™: Alkermes scored higher than 95% of companies evaluated by MarketBeat, and ranked 80th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAlkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 7 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageAlkermes has only been the subject of 4 research reports in the past 90 days.Read more about Alkermes' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth-6.36% Earnings GrowthEarnings for Alkermes are expected to decrease by -6.36% in the coming year, from $2.36 to $2.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is 16.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.32.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is 16.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.15.Price to Earnings Growth RatioAlkermes has a PEG Ratio of 0.56. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 3.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alkermes' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.15% of the outstanding shares of Alkermes have been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Alkermes has recently decreased by 7.73%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.17 Percentage of Shares Shorted10.15% of the outstanding shares of Alkermes have been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Alkermes has recently decreased by 7.73%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment0.41 News SentimentAlkermes has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Alkermes this week, compared to 6 articles on an average week.Search Interest4 people have searched for ALKS on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Alkermes to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.89% of the stock of Alkermes is held by insiders.Percentage Held by Institutions95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alkermes' insider trading history. Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address ALKS Stock News HeadlinesAlkermes to Report Third Quarter Financial Results on October 24, 2024October 17 at 4:00 PM | prnewswire.comAlkermes plc (NASDAQ:ALKS) Sees Large Decrease in Short InterestOctober 16 at 4:45 AM | americanbankingnews.com$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.October 17, 2024 | Insiders Exposed (Ad)Alkermes Public Limited CompanyOctober 16 at 12:14 AM | cnn.comAlkermes (NASDAQ:ALKS) Receives "Neutral" Rating from HC WainwrightOctober 15 at 4:45 AM | americanbankingnews.comQ2 2025 EPS Estimates for Alkermes plc Decreased by Zacks Research (NASDAQ:ALKS)October 15 at 1:47 AM | americanbankingnews.comAnalysts Conflicted on These Healthcare Names: Nurix Therapeutics (NRIX) and Alkermes (ALKS)October 14 at 2:59 PM | markets.businessinsider.comAssessing Alkermes’ ALKS-2680: A Hold Rating amidst Potential and Prudence in Sleep Disorder TreatmentOctober 14 at 2:59 PM | markets.businessinsider.comSee More Headlines ALKS Stock Analysis - Frequently Asked Questions How have ALKS shares performed this year? Alkermes' stock was trading at $27.74 at the start of the year. Since then, ALKS shares have increased by 2.1% and is now trading at $28.33. View the best growth stocks for 2024 here. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) issued its quarterly earnings data on Wednesday, July, 24th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. The firm's revenue for the quarter was down 35.4% on a year-over-year basis. Is Alkermes doing a stock buyback? Alkermes' board approved a stock buyback plan on Thursday, February 15th 2024, which allows the company to buy back $400,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 8.2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board of directors believes its shares are undervalued. Does Alkermes have any subsidiaries? The following companies are subsidiaries of Alkermes: Rodin Therapeutics. Who are Alkermes' major shareholders? Top institutional shareholders of Alkermes include Handelsbanken Fonder AB (0.13%), Vontobel Holding Ltd. (0.03%), Creative Planning (0.03%) and Diversified Trust Co (0.02%). Insiders that own company stock include Richard F Pops, Michael J Landine, Shane Cooke, Blair Curtis Jackson, Christian Todd Nichols, Nancy Wysenski, Cato T Laurencin and Craig C Hopkinson. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alkermes investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings7/24/2024Today10/17/2024Next Earnings (Estimated)10/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALKS CUSIPG0176710 CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,100Year Founded1987Price Target and Rating Average Stock Price Target$36.70 High Stock Price Target$50.00 Low Stock Price Target$25.00 Potential Upside/Downside+29.5%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$2.53 Trailing P/E Ratio16.86 Forward P/E Ratio12.00 P/E Growth0.56Net Income$355.76 million Net Margins19.15% Pretax Margin20.87% Return on Equity23.20% Return on Assets13.52% Debt Debt-to-Equity Ratio0.22 Current Ratio2.99 Quick Ratio2.61 Sales & Book Value Annual Sales$1.51 billion Price / Sales3.18 Cash Flow$2.42 per share Price / Cash Flow11.72 Book Value$7.21 per share Price / Book3.93Miscellaneous Outstanding Shares169,221,000Free Float156,616,000Market Cap$4.79 billion OptionableOptionable Beta0.46 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ALKS) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.